Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors.

There is significant debate regarding high-density lipoprotein cholesterol (HDL-C) and high-fiber, low-fat diets. The present study was designed to examine the effects of lifestyle modification on the inflammatory/anti-inflammatory properties of HDL in obese men (n = 22) with metabolic syndrome factors. Subjects were placed on a high-fiber, low-fat diet in a 3-wk residential program where food was provided ad libitum and daily aerobic exercise was performed. Fasting blood was drawn pre- and postintervention for serum lipids, lipid hydroperoxides, and the ability of subject HDL to alter low-density lipoprotein (LDL)-induced monocyte chemotactic activity (MCA) in a human artery wall coculture. Induction of MCA by control LDL in the absence of HDL was normalized to 1.0. Values >1.0 after HDL addition indicated proinflammatory HDL; values <1.0 indicated anti-inflammatory HDL. In addition, proteins involved in regulating HDL function, apolipoprotein A-I (apoA-I), paraoxonase 1 and 3, and platelet-activating factor acetylhydrolase were measured. After 3 wk, decreases in total-cholesterol, LDL-cholesterol, HDL-C, triglycerides, total cholesterol-to-HDL cholesterol ratio, and lipid hydroperoxides (all P < 0.05) were noted. The HDL inflammatory index decreased (P < 0.05) from pro- (1.14 +/- 0.11) to anti-inflammatory (0.94 +/- 0.09). ApoA-I level and paraoxonase activity did not change; however, platelet-activating factor acetylhydrolase activity increased (P < 0.05). Despite a quantitative reduction in HDL-C, HDL converted from pro- to anti-inflammatory. These data indicate that intensive lifestyle modification improves the function of HDL even in the face of reduced levels, suggesting increased turnover of proinflammatory HDL.

[1]  N. Vaziri,et al.  Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. , 2006, Journal of applied physiology.

[2]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[3]  S. Hazen,et al.  Formation of dysfunctional high-density lipoprotein by myeloperoxidase. , 2005, Trends in cardiovascular medicine.

[4]  S. Reddy,et al.  The double jeopardy of HDL , 2005, Annals of medicine.

[5]  E. Ninio.  Phospholipid mediators in the vessel wall: involvement in atherosclerosis , 2005, Current opinion in clinical nutrition and metabolic care.

[6]  W. März,et al.  Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors: The Ludwigshafen Risk and Cardiovascular Health Study , 2005, Circulation.

[7]  R. Tyrrell,et al.  Exercise-induced expression of heme oxygenase-1 in human lymphocytes , 2005, Free radical research.

[8]  A. Fogelman.  When good cholesterol goes bad , 2004, Nature Medicine.

[9]  Michael Kinter,et al.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. , 2004, The Journal of clinical investigation.

[10]  C. Roberts,et al.  Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. , 2004, Metabolism: clinical and experimental.

[11]  Shirin Rahmani,et al.  Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin Treatment , 2003, Circulation.

[12]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[13]  N. Vaziri,et al.  Effect of Diet and Exercise Intervention on Blood Pressure, Insulin, Oxidative Stress, and Nitric Oxide Availability , 2002, Circulation.

[14]  M. Navab,et al.  Oxidized lipids as mediators of coronary heart disease , 2002, Current opinion in lipidology.

[15]  Doris A Taylor,et al.  Cardiac chimerism as a mechanism for self-repair: does it happen and if so to what degree? , 2002, Circulation.

[16]  M. Jauhiainen,et al.  Dietary determinants of serum paraoxonase activity in healthy humans. , 2002, Atherosclerosis.

[17]  P. Ridker.  On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. , 2002, Circulation.

[18]  S. Reddy,et al.  High-density lipoprotein and the dynamics of atherosclerotic lesions. , 2001, Circulation.

[19]  S. Reddy,et al.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.

[20]  S. Reddy,et al.  Mitogen-activated Protein Kinase Phosphatase 1 Activity Is Necessary for Oxidized Phospholipids to Induce Monocyte Chemotactic Activity in Human Aortic Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[21]  D. Nayak,et al.  High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection , 2001, Circulation.

[22]  D. Shih,et al.  Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[23]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[24]  S. Reddy,et al.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.

[25]  G. Fonarow,et al.  formation of , 2022 .

[26]  R. Barnard,et al.  Effects of an intensive diet and exercise program on lipids in postmenopausal women. , 1999, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[27]  A. Lichtenstein,et al.  Very-low fat diets. , 1999, Circulation.

[28]  L. Tjoelker,et al.  Human plasma platelet-activating factor acetylhydrolase. , 1999, Methods in molecular biology.

[29]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[30]  G. Zimmerman,et al.  Platelet-activating Factor Acetylhydrolases* , 1997, The Journal of Biological Chemistry.

[31]  A. von Eckardstein,et al.  High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. , 1996, Atherosclerosis.

[32]  D. Stafforini,et al.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. , 1995, The Journal of clinical investigation.

[33]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[34]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[35]  B. Auerbach,et al.  A spectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. , 1992, Analytical biochemistry.

[36]  A. J. Valente,et al.  Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. , 1991, The Journal of clinical investigation.

[37]  Barnard Rj.  Effects of Life-style Modification on Serum Lipids , 1991 .

[38]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. , 1991, The Journal of biological chemistry.

[39]  A. Smolen,et al.  PURIFICATION OF HUMAN SERUM PARAOXONASE/ARYLESTERASE , 1991 .

[40]  A. Smolen,et al.  Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[41]  R. Barnard,et al.  Effects of life-style modification on serum lipids. , 1991, Archives of internal medicine.

[42]  D. Stafforini,et al.  Platelet-activating factor acetylhydrolase from human plasma. , 1990, Methods in enzymology.

[43]  S. Eisenberg,et al.  A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. , 1990, The Journal of clinical investigation.

[44]  M. Territo,et al.  Modification of the Recalde method for the isolation of human monocytes. , 1988, Journal of lipid research.

[45]  P. Wilson,et al.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. , 1986, JAMA.

[46]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[47]  R. Mahley,et al.  DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH SIGNIFICANT LIPOPROTEIN MODIFICATIONS AND WITHOUT CLINICAL ATHEROSCLEROSIS IN AN ITALIAN FAMILY , 1980 .

[48]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[49]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.